The market for oncology companion diagnostics is poised for significant growth, according to Sagient Research Systems, an Informa company. Estimated at $2.55 billion for the top six indications (breast, ovarian, colon, endometrial, and pancreatic cancer, and melanoma), the US market for oncology companion diagnostics is projected to reach at least $3.29 billion by 2018.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?